Table 1.
Characteristics of the included studies
| Disease | Citation | Publication type | Country | Drug | Study type | Patient follow-up | Cohort size | Switch program |
|---|---|---|---|---|---|---|---|---|
| Dermatology | ||||||||
| Psoriasis | Szlumper [9] | Abstract | UK | Etanercept | Center-based cohort study | 3 months | 17 | NS |
| Gastroenterology | ||||||||
| CD | Ala [50] | Abstract | UK | Infliximab | Center-based cohort study | 6 months | 20 | NS |
| CD | Plevris [45] | Journal article | UK | Infliximab | Center-based cohort study (prospective) | 12 months | 110 | Yes |
| IBD | O'Brien [84] | Abstract | Ireland | Infliximab | Center-based cohort study | NR | 20 | NS |
| CD, UC | Bergqvist [51] | Journal article | Sweden | Infliximab | Center-based cohort study (prospective) | 12 months | 313 | NS |
| CD, UC | Diaz Hernandez [52] | Abstract | Spain | Infliximab | Center-based cohort study (retrospective) | 6 months | 72 | NS |
| CD, UC | Fischer [53] | Abstract | Germany | Infliximab | Center-based cohort study (prospective) | 6 months | 114 | NS |
| CD, UC | Geccherle [85] | Abstract | Italy | Infliximab | Center-based cohort study | 6 months | 5 | NS |
| CD, UC | Guerra Veloz [54] | Journal article | Spain | Infliximab | Center-based cohort study (prospective) | 24 months | 100 | NS |
| CD, UC | Hoivik [55] | Journal article | Norway | Infliximab | Center-based cohort study (prospective) | 18 months | 143 | NS |
| CD, UC | Kim [86] | Journal article | Korea | Infliximab | Center-based cohort study (retrospective) | 60 months | 101 | NS |
| CD, UC | Rahmany [38] | Abstract | UK | Infliximab | Center-based cohort study | NR | 78 | Yes |
| CD, UC | Rodriguez Glez [56] | Abstract | Spain | Infliximab | Center-based cohort study (retrospective) | 12 months | 72 | NS |
| CD, UC | Sieczkowska [57] | Journal article | Poland | Infliximab | Center-based cohort study (prospective) | 11 months | 39 | NS |
| CD, UC | St Clair Jones [39] | Abstract | UK | Infliximab | Center-based cohort study | 6 months | 71 | Yes |
| Pediatric CD, UC | Kang [58] | Abstract | South Korea | Infliximab | Center-based cohort study (prospective) | 1 year | 38 | NS |
| CD, UC, IBDU | Huoponen [35] | Journal article | Finland | Infliximab | Center-based cohort study (prospective) | 12 months | 54 | NS |
| CD, UC, IBDU | Smits [59] | Journal article | Netherlands | Infliximab | Center-based cohort study (prospective) | 12 months | 83 | NS |
| CD, UC, IBDU | Razanskaite [44] | Journal article | UK | Infliximab | Center-based cohort study | 12 months | 143 | Yes |
| CD, FCD, UC | Park [60] | Journal article | South Korea | Infliximab | Post-marketing study | 30 weeks | 60 | NS |
| LCD, FCD, UC, IBDU | Ratnakumaran [61] | Journal article | UK | Infliximab | Center-based cohort study | 12 months | 191 | NS |
| NS | Gervais [62] | Journal article | UK | Infliximab | Center-based cohort study (prospective) | 12 months | 33 | NS |
| Rheumatology | ||||||||
| RA | Dyball [63] | Abstract | UK | Etanercept | Center-based cohort study (retrospective) | N/A | 38 | NS |
| RA | Peral [37] | Abstract | Spain | Etanercept | Decision tree model with physician survey | NR | NS | NS |
| RA | Shah [43] | Abstract | UK | Etanercept | Center-based cohort study (prospective) | 4 months | 151 | Yes |
| RA | Tarallo [32] | Journal article | UK | Etanercept | Simulation model with physician survey | NR | 1,259 | NS |
| RA | Nisar [64] | Abstract | UK | Rituximab | Center-based cohort study | NR | 40 | NS |
| RA, PsA, AS | Alkoky [71] | Abstract | UK | Etanercept | Center-based cohort study (prospective) | 6 months | 158 | NS |
| RA, PsA, AS | Barnes [40] | Abstract | UK | Etanercept | Interview | NR | 149–180/center, 4 centers | Yes |
| RA, PsA, AS | Chan [41] | Journal article | UK | Etanercept | Center-based cohort study | NR | 113 | Yes |
| RA, PsA, AS | Dayer [87] | Abstract | Spain | Etanercept | Center-based cohort study (retrospective) | NR | 31 | NS |
| RA, PsA, AS | Ma [65] | Abstract | UK | Etanercept | Center-based cohort study | 6 months | 160 | NS |
| RA, PsA, AS | Gibofsky [34] | Abstract | UK, Germany | Infliximab | Database (retrospective) | 12 months | 119 | NS |
| RA, PsA, AS | Glintborg [33] | Journal article | Denmark | Infliximab | Center-based cohort study | 6 months | 769 | NS |
| RA, PsA, AS | Nascimento Junior [66] | Abstract | Brazil | Infliximab | Center-based cohort study (prospective) | NR | 78 | NS |
| RA, PsA, AS, JIA | Nisar [42] | Abstract | UK | Etanercept | Center-based cohort study | 1 year | 82 | Yes |
| RA, PsA, SpA | Uke [72] | Abstract | UK | Etanercept | Database | min 3 months | 157 | NS |
| RA, PsA, SpA | Valido [67] | Abstract | Portugal | Infliximab | Center-based cohort study (prospective) | median 15 months | 60 | NS |
| NS | Ahmad [68] | Abstract | UK | Etanercept | Interview | NR | 104 | NS |
| NS | Moron [88] | Abstract | Spain | Etanercept | Center-based cohort study (retrospective) | 9 months | 30a | NS |
| NS | Sheppard [73] | Abstract | UK | Infliximab | Center-based cohort study | 12 months | 25 | NS |
| Hepatology | ||||||||
| Chronic kidney disease | Minutolo [8] | Journal article | Italy | ESA | Center-based cohort study (retrospective) | 24 weeks | 163 | NS |
| Oncology | ||||||||
| Solid tumors, hematological malignancy | Al Rabayah [6] | Abstract | Jordan | Filgrastim | Center-based cohort study (retrospective) | NR | 37 | NS |
| Growth development | ||||||||
| GHD, TS, CRI, PWS, children born small for gestational age | Flodmark [7] | Journal article | Sweden | Somatropin | Center-based cohort study | NR | 98 | NS |
| Unspecified or multiple disease areas | ||||||||
| IBD, RA, PsA, AS | Abdalla [69] | Journal article | UK | Infliximab | Center-based cohort study (prospective and retrospective) | Mean 15.8 months | 34 | NS |
| NS (areas include rheumatology, gastroentology, internal medicine) | Gutermann [70] | Abstract | France | Infliximab | Center-based cohort study | 10 months | 267 | NS |
| CD, UC, RA, AS | Ramos Rodriguez [74] | Abstract | Spain | Infliximab | Center-based cohort study (retrospective) | 11 months | 48 | NS |
| NS (RA, AS most common) | Phillips [36] | Abstract | Turkey | Infliximab | Database | NR | 136 | NS |
| NS | Zahorian [89] | Abstract | USA | Infliximab | Center-based cohort study | NR | 100 | NS |
AS axial spondylarthritis, CD Crohn's disease, CRI chronic renal insufficiency, FCD fistulizing Crohn’s disease, GHD growth hormone deficiency, IBD inflammatory bowel disease, IBDU inflammatory bowel disease unclassified, JIA juvenile idiopathic arthritis, LCD luminal Crohn’s disease, NMS non-medical switch, NR not reported, NS not specified, PsA psoriatic arthritis, PWS Prader–Willi Syndrome, RA rheumatoid arthritis, SpA spondylarthritis, TS Turner syndrome, UC ulcerative colitis, UK United Kingdom, USA United States of America
aThe selected cohort of 30 patients included all patients treated with etanercept biosimilar since its incorporation into the pharmacotherapeutic guide of the hospital. The number of patients switched from the reference biologic is not specified